Skip to content

JASCO JASCO

  • News
  • Events
  • E-Store
  • My Account
  • Contact Us
  • Worldwide
Search
Click to view menu
  • Products
    • Chromatography
      • HPLC
      • RHPLC
      • UHPLC
      • LC-MS
      • Preparative LC
      • Analytical SFC
      • Semi-Preparative SFC
      • Hybrid SFC
      • Fuel Analysis by SFC-FID
      • Preparative SFC
      • Supercritical Fluid Extraction
      • Chromatography Software
    • Molecular Spectroscopy
      • Circular Dichroism
      • High-Throughput CD
      • Vibrational CD
      • Circularly Polarized Luminescence (CPL)
      • Polarimeters
      • FTIR Spectrometers
      • FTIR Microscopy
      • FTIR Portable
      • Raman Microscopy
      • Palmtop Raman Spectrometer
      • Probe Raman
      • UV-Visible/NIR Spectrophotometers
      • UV-Visible/NIR Microscopy
      • Fluorescence Spectrophotometers
      • Film Thickness
      • Spectra Manager™ Suite
    • Refurbished
      • Refurbished HPLC Systems
      • HPLC Switching Valves
      • FTIR Accessories
  • Service
    • Service and Support Plans
    • Service Request Form
  • Applications
  • KnowledgeBase
  • Learning Center
    • Best Practice
      • Circular Dichroism Tips & Tricks for Biological Samples
      • CD Scale Calibration with ACS
      • Fluorescence Tips & Tricks
      • Raman Spectroscopy Tips & Tricks
    • Training Videos
      • ChromNAV
      • SF-NAV
      • Circular Dichroism
      • UV-Visible/NIR
      • Fluorescence
    • Training Seminars
      • Training Registration Form
    • Webinars
    • eBooks
    • Theory
      • Theory of Molecular Spectroscopy
      • Chromatography
  • About Us
    • President’s Message
    • Contact
    • History
    • Careers
  • News
  • Events
  • Worldwide
  • Shop
  • My Account
  • Contact Us

Home / Applications / Evaluation of Higher-Order Structure and Stability of mRNA-based Therapeutics by Circular Dichroism Spectroscopy

  • Industry

  • Technique

Evaluation of Higher-Order Structure and Stability of mRNA-based Therapeutics by Circular Dichroism Spectroscopy

By Spectroscopy Team

PDF IconDownload This Application

April 2, 2025

Introduction

Fig. 1 Schematic diagram of mRNA–LNP

The discovery of modified nucleic acids that reduce the immunogenicity of messenger RNA (mRNA) and the establishment of lipid nanoparticle (LNP)-based drug delivery technology have led to widespread research on mRNA pharmaceutical applications1). In particular, since mRNA vaccines play a major role in the termination of new coronavirus infection (COVID-19), research and development of mRNA medicine has attracted much attention. mRNA medicines have the potential to treat various unmet medical needs or operate as vaccines, since they can be developed rapidly. As of May 2023, more than 100 mRNA products have reached the clinical trial stage2,3). Since low thermal stability is one of the challenges in transportation and storage of mRNA medicines, clarification of the higher-order structure, stability, and physicochemical properties of mRNA in LNP formulation will lead to the development of robust mRNA medicines4).

Fig.2 A-form RNA. CD spectrum

Circular dichroism (CD) spectroscopy is widely known as a method for rapidly evaluating the higher-order structure of biological macromolecules such as proteins and nucleic acids at low concentration5,6). Structural changes in proteins and nucleic acids caused by perturbations such as heat, pH, additives, and chemical denaturants can be tracked by CD spectroscopy making it an effective tool in the research and development of pharmaceuticals.

Here, we introduce an application that evaluates the thermal stability of mRNA particles formed using LNP by taking advantage of the features of CD spectroscopy.

Experimental

Fig.3 Measurement system, J-1500

Sample

0.1 mg/mL mRNA:  mRNA
0.1 mg/mL mRNA encapsulated in LNP :   mRNA/LNP
0.1 mg/mL  empty LNP:  LNP

*All samples were dissolved in 1xPBS and measured using 1 mm CD quartz cells.

System

Instrument:   J-1500 circular dichroism spectrometer
Attachments:   PTC-510, CTU-100

Measurement Conditions

Wavelength Range205 nm-320 nmScan Speed50 nm/min
Response4 secBand Width1.0 nm
Data Interval0.1 nmScan4
Optical Path Length1 mmTemperature Range25ºC – 95ºC
Heating Rate1ºC /min2ºC step

 

 

Keywords

mRNA-based therapeutics, Vaccine, LNP, Nucleic acid, Circular dichroism spectroscopy, CD, Thermal stability

Results

CD spectra of mRNA, LNP and mRNA/LNP

Fig. 4 CD spectra of each sample

The CD spectra and standard deviation area of each sample at room temperature are shown in Fig. 4. The standard deviation of the spectra was calculated using 3 replicates for each sample. The CD spectrum of mRNA shows a negative peak at 210 nm and a positive peak at 265 nm, indicating the abundance of typical A-type double helix structure. The CD spectrum of LNP showed a negative peak at 207 nm, but other wavelengths did not show peaks that interfere with the mRNA CD spectrum7). The mRNA/LNP was found to contain abundant type A double helix structures.

Conformational change of mRNA by encapsulated in LNP

Fig. 5 CD spectra of mixed and encapsulated mRNA

To confirm whether the structure of mRNA is changed by encapsulation, we compared the CD spectra of mRNA/LNP (encapsulated) and mRNA mixed with equimolar LNP (Fig. 5). The two CD spectra in Fig. 5 would match if there is no change in the structure of mRNA and LNPs due to mRNA encapsulated. However, a differences greater than the standard deviation is observed in these CD spectra near 210 nm and 265 nm region indicative of structural changing of mRNA and LNPs due to encapsulation.

Heat-induced conformational changes of mRNA, LNP and mRNA/LNP

For each sample, we measured the temperature-ramping CD spectra from 25-95ºC. mRNA alone showed a loss of the peak intensity near 210 nm upon heating. The positive peak at 265 nm shifted to 270 nm while decreasing in intensity (Fig. 6a). This indicates that base pairing and stacking collapse upon heating and the presence of a single-stranded mRNA coil dominates. In LNP, the peak near 207 nm disappeared with heating (Fig. 6b). This may indicate that the cholesterol orientation in LNP is lost as LNP collapse. Similar to the changes observed for mRNA alone, changes in the CD spectra of the mRNA/LNP were also observed upon heating, which were thought to be due to the decay of mRNA base pairs and LNPs (Fig. 6c).

Fig. 6 Temperature-ramping CD spectra of each sample
a) mRNA b) LNP c) mRNA/LNP
Each CD spectrum is offset so that the CD value at 320 nm is zero.

Comparison of thermal stability between mRNA and mRNA/LNP

Fig. 7 Melting curve of mRNA and mRNA/LNP

To confirm whether the thermal stability of mRNA is altered by encapsulation with LNPs, we evaluated the peak shift around 250-290 nm in the temperature-ramping CD spectra of mRNA and mRNA/LNP. As mentioned above, a shift of the peak position to longer wavelengths indicates base pair dissociation and denaturation of the higher-order structure of mRNA. The peak shift was calculated from the barycentric mean of the spectrum (Eq. 1), and the relative ratio of denatured mRNA was calculated by normalizing the data between the 25ºC and 95ºC peak positions (Fig. 7), assuming complete higher-order structure formation at 25ºC and complete higher-order structure denaturation at 95ºC. By fitting both data using the Hill equation (Eq. 2), the denaturation midpoint (Tm), a measure of thermal stability, and the Hill coefficient, a measure of cooperative collapse of higher-order structures, were obtained. The results showed that encapsulation mRNA exhibited higher Tm and Hill coefficient than mRNA alone, indicating that the higher-order structure of mRNA is stabilized by encapsulation. This trend is consistent with the report by Brader et al.4).

Tm/°CHill coef.
mRNA69.98.4
mRNA/LNP77.612.9

Conclusion

By using CD spectroscopy, we were able to evaluate mRNA structure, conformational change by encapsulation in LNP, and thermal stability. CD spectroscopy allows easy characterization of mRNA structure under various conditions such as pH, salt, and additives as well as heat.

References

1.V. Gote, PK. Bolla, N. Kommineni, A. Butreddy, PK. Nukala, SS. Palakurthi, W. Khan: Int J Mol Sci., 31, 2700 (2023). DOI: 10.3390/ijms24032700

2.M. Metkar, C.S. Pepin, M.J. Moore: Nat Rev Drug Discov, 23, 67 (2024). DOI: 10.1038/s41573-023-00827-x

3.T. Yoshida, T. Yamashita, T. Yamamoto, N. Ohoka, K. Itaka, H. Akita, F. Takeshita, J. Mineo, S. Tsujihata, T. Yamaguchi, E. Uchida, T. Inoue,: PMDRS, 54, 4, 3222 (2023).

4.M. Kloczewiak, JM. Banks, L. Jin, ML. Brader: Mol Pharm., 4, 2022 (2022). DOI:10.1021/acs.molpharmaceut.2c00092

5.A. Micsonai, É. Bulyáki, J. Kardos: Methods in molecular biology (Clifton, N.J.), 2199, 175–189 (2021).

6.J. Kypr, I. Kejnovská, D. Renciuk, M. Vorlícková: Nucleic Acids Res., 37, 1713 (2009). DOI: 10.1093/nar/gkp026.

7.J. Anindita, H. Tanaka, T. Yamakawa, Y. Sato, C. Matsumoto, K. Ishizaki, T. Oyama, S. Suzuki, K. Ueda, K. Higashi, K. Moribe, K. Sasaki, Y. Ogura, E. Yonemochi, Y. Sakurai, H. Hatakeyama, H. Akita: Pharmaceutics, 26 (2024). DOI: 10.3390/pharmaceutics16020181.

 

This application has been developed with the help of Professor Hidetaka Akita, Associate Professor Hiroki Tanaka, and Dr. Yu Sakurai of the Department of Drug Delivery, Tohoku University, who provided us with samples.

This document has been prepared based on information available at the time of publication and is subject to revision without notice. Although the contents are checked with the utmost care, we do not guarantee their accuracy or completeness. JASCO Corporation assumes no responsibility or liability for any loss or damage incurred as a result of the use of any information contained in this document. Copyright and other intellectual property rights in this document remain the property of JASCO Corporation. Please do not attempt to copy, modify, redistribute, or sell etc. in whole or in part without prior written permission.

About the Author

JASCO Application Note

Evaluation of Higher-Order Structure and Stability of mRNA-based Therapeutics by Circular Dichroism Spectroscopy

Introduction

Fig. 1 Schematic diagram of mRNA–LNP

The discovery of modified nucleic acids that reduce the immunogenicity of messenger RNA (mRNA) and the establishment of lipid nanoparticle (LNP)-based drug delivery technology have led to widespread research on mRNA pharmaceutical applications1). In particular, since mRNA vaccines play a major role in the termination of new coronavirus infection (COVID-19), research and development of mRNA medicine has attracted much attention. mRNA medicines have the potential to treat various unmet medical needs or operate as vaccines, since they can be developed rapidly. As of May 2023, more than 100 mRNA products have reached the clinical trial stage2,3). Since low thermal stability is one of the challenges in transportation and storage of mRNA medicines, clarification of the higher-order structure, stability, and physicochemical properties of mRNA in LNP formulation will lead to the development of robust mRNA medicines4).

Fig.2 A-form RNA. CD spectrum

Circular dichroism (CD) spectroscopy is widely known as a method for rapidly evaluating the higher-order structure of biological macromolecules such as proteins and nucleic acids at low concentration5,6). Structural changes in proteins and nucleic acids caused by perturbations such as heat, pH, additives, and chemical denaturants can be tracked by CD spectroscopy making it an effective tool in the research and development of pharmaceuticals.

Here, we introduce an application that evaluates the thermal stability of mRNA particles formed using LNP by taking advantage of the features of CD spectroscopy.

Experimental

Fig.3 Measurement system, J-1500

Sample

0.1 mg/mL mRNA:  mRNA
0.1 mg/mL mRNA encapsulated in LNP :   mRNA/LNP
0.1 mg/mL  empty LNP:  LNP

*All samples were dissolved in 1xPBS and measured using 1 mm CD quartz cells.

System

Instrument:   J-1500 circular dichroism spectrometer
Attachments:   PTC-510, CTU-100

Measurement Conditions

Wavelength Range205 nm-320 nmScan Speed50 nm/min
Response4 secBand Width1.0 nm
Data Interval0.1 nmScan4
Optical Path Length1 mmTemperature Range25ºC – 95ºC
Heating Rate1ºC /min2ºC step

 

 

Results

CD spectra of mRNA, LNP and mRNA/LNP

Fig. 4 CD spectra of each sample

The CD spectra and standard deviation area of each sample at room temperature are shown in Fig. 4. The standard deviation of the spectra was calculated using 3 replicates for each sample. The CD spectrum of mRNA shows a negative peak at 210 nm and a positive peak at 265 nm, indicating the abundance of typical A-type double helix structure. The CD spectrum of LNP showed a negative peak at 207 nm, but other wavelengths did not show peaks that interfere with the mRNA CD spectrum7). The mRNA/LNP was found to contain abundant type A double helix structures.

Conformational change of mRNA by encapsulated in LNP

Fig. 5 CD spectra of mixed and encapsulated mRNA

To confirm whether the structure of mRNA is changed by encapsulation, we compared the CD spectra of mRNA/LNP (encapsulated) and mRNA mixed with equimolar LNP (Fig. 5). The two CD spectra in Fig. 5 would match if there is no change in the structure of mRNA and LNPs due to mRNA encapsulated. However, a differences greater than the standard deviation is observed in these CD spectra near 210 nm and 265 nm region indicative of structural changing of mRNA and LNPs due to encapsulation.

Heat-induced conformational changes of mRNA, LNP and mRNA/LNP

For each sample, we measured the temperature-ramping CD spectra from 25-95ºC. mRNA alone showed a loss of the peak intensity near 210 nm upon heating. The positive peak at 265 nm shifted to 270 nm while decreasing in intensity (Fig. 6a). This indicates that base pairing and stacking collapse upon heating and the presence of a single-stranded mRNA coil dominates. In LNP, the peak near 207 nm disappeared with heating (Fig. 6b). This may indicate that the cholesterol orientation in LNP is lost as LNP collapse. Similar to the changes observed for mRNA alone, changes in the CD spectra of the mRNA/LNP were also observed upon heating, which were thought to be due to the decay of mRNA base pairs and LNPs (Fig. 6c).

Fig. 6 Temperature-ramping CD spectra of each sample
a) mRNA b) LNP c) mRNA/LNP
Each CD spectrum is offset so that the CD value at 320 nm is zero.

Comparison of thermal stability between mRNA and mRNA/LNP

Fig. 7 Melting curve of mRNA and mRNA/LNP

To confirm whether the thermal stability of mRNA is altered by encapsulation with LNPs, we evaluated the peak shift around 250-290 nm in the temperature-ramping CD spectra of mRNA and mRNA/LNP. As mentioned above, a shift of the peak position to longer wavelengths indicates base pair dissociation and denaturation of the higher-order structure of mRNA. The peak shift was calculated from the barycentric mean of the spectrum (Eq. 1), and the relative ratio of denatured mRNA was calculated by normalizing the data between the 25ºC and 95ºC peak positions (Fig. 7), assuming complete higher-order structure formation at 25ºC and complete higher-order structure denaturation at 95ºC. By fitting both data using the Hill equation (Eq. 2), the denaturation midpoint (Tm), a measure of thermal stability, and the Hill coefficient, a measure of cooperative collapse of higher-order structures, were obtained. The results showed that encapsulation mRNA exhibited higher Tm and Hill coefficient than mRNA alone, indicating that the higher-order structure of mRNA is stabilized by encapsulation. This trend is consistent with the report by Brader et al.4).

Tm/°CHill coef.
mRNA69.98.4
mRNA/LNP77.612.9

Conclusion

By using CD spectroscopy, we were able to evaluate mRNA structure, conformational change by encapsulation in LNP, and thermal stability. CD spectroscopy allows easy characterization of mRNA structure under various conditions such as pH, salt, and additives as well as heat.

Keywords

mRNA-based therapeutics, Vaccine, LNP, Nucleic acid, Circular dichroism spectroscopy, CD, Thermal stability

References

1.V. Gote, PK. Bolla, N. Kommineni, A. Butreddy, PK. Nukala, SS. Palakurthi, W. Khan: Int J Mol Sci., 31, 2700 (2023). DOI: 10.3390/ijms24032700

2.M. Metkar, C.S. Pepin, M.J. Moore: Nat Rev Drug Discov, 23, 67 (2024). DOI: 10.1038/s41573-023-00827-x

3.T. Yoshida, T. Yamashita, T. Yamamoto, N. Ohoka, K. Itaka, H. Akita, F. Takeshita, J. Mineo, S. Tsujihata, T. Yamaguchi, E. Uchida, T. Inoue,: PMDRS, 54, 4, 3222 (2023).

4.M. Kloczewiak, JM. Banks, L. Jin, ML. Brader: Mol Pharm., 4, 2022 (2022). DOI:10.1021/acs.molpharmaceut.2c00092

5.A. Micsonai, É. Bulyáki, J. Kardos: Methods in molecular biology (Clifton, N.J.), 2199, 175–189 (2021).

6.J. Kypr, I. Kejnovská, D. Renciuk, M. Vorlícková: Nucleic Acids Res., 37, 1713 (2009). DOI: 10.1093/nar/gkp026.

7.J. Anindita, H. Tanaka, T. Yamakawa, Y. Sato, C. Matsumoto, K. Ishizaki, T. Oyama, S. Suzuki, K. Ueda, K. Higashi, K. Moribe, K. Sasaki, Y. Ogura, E. Yonemochi, Y. Sakurai, H. Hatakeyama, H. Akita: Pharmaceutics, 26 (2024). DOI: 10.3390/pharmaceutics16020181.

 

This application has been developed with the help of Professor Hidetaka Akita, Associate Professor Hiroki Tanaka, and Dr. Yu Sakurai of the Department of Drug Delivery, Tohoku University, who provided us with samples.

This document has been prepared based on information available at the time of publication and is subject to revision without notice. Although the contents are checked with the utmost care, we do not guarantee their accuracy or completeness. JASCO Corporation assumes no responsibility or liability for any loss or damage incurred as a result of the use of any information contained in this document. Copyright and other intellectual property rights in this document remain the property of JASCO Corporation. Please do not attempt to copy, modify, redistribute, or sell etc. in whole or in part without prior written permission.
28600 Mary’s Court, Easton, MD 21601 USA • (800) 333-5272 • Fax: (410) 822-7526 • jascoinc.com/applications

Close

Designed in Tokyo. TRUSTED globally.

View our support plans

Connect with JASCO

  • Facebook
  • Twitter
  • LinkedIn
  • JASCO Sales
  • 800-333-5272

Receive the latest promotions and special offers

  • This field is for validation purposes and should be left unchanged.
  • Careers
  • Press Kit
  • JASCO Privacy Policy
  • Sitemap
  • Environmental Policy

© , JASCO. All Rights Reserved.